News stories about ABIOMED (NASDAQ:ABMD) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ABIOMED earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 46.2151442485318 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
ABIOMED (NASDAQ ABMD) traded up $0.27 during mid-day trading on Wednesday, reaching $233.99. 313,800 shares of the company’s stock traded hands, compared to its average volume of 392,301. The stock has a market cap of $10,348.61, a PE ratio of 124.55, a P/E/G ratio of 3.10 and a beta of 0.36. ABIOMED has a 12-month low of $108.21 and a 12-month high of $255.42.
ABIOMED (NASDAQ:ABMD) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.20. The firm had revenue of $154.00 million during the quarter, compared to analysts’ expectations of $154.00 million. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. ABIOMED’s revenue for the quarter was up 34.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.34 EPS. analysts predict that ABIOMED will post 2.39 EPS for the current year.
A number of equities research analysts recently commented on ABMD shares. Piper Jaffray Companies raised their price objective on shares of ABIOMED to $200.00 and gave the company an “overweight” rating in a research report on Thursday, October 26th. Zacks Investment Research upgraded shares of ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price objective for the company in a research report on Tuesday, November 7th. Jefferies Group raised their price objective on shares of ABIOMED from $208.00 to $220.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. BidaskClub upgraded shares of ABIOMED from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 20th. Finally, Leerink Swann lifted their price target on shares of ABIOMED from $200.00 to $265.00 and gave the company an “outperform” rating in a research report on Friday, January 19th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. ABIOMED has an average rating of “Buy” and a consensus target price of $263.86.
WARNING: “ABIOMED (NASDAQ:ABMD) Receives Daily Media Sentiment Score of 0.20” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-abiomed-abmd-share-price.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.